1. A method for forming an integral assembly, the method comprising:
positioning a transparent member in a mold;
providing a liquid metal into the mold; and
hardening the liquid metal, wherein hardening the liquid metal includes binding the liquid metal to the transparent member to create the integral assembly.
2. The method of claim 1 wherein the transparent member is glass and the liquid metal is LiquidMetal.
3. The method of claim 1 wherein the transparent member includes at least one retaining feature, the retaining feature being positioned at an edge of the transparent member, the retaining feature being arranged to facilitate binding between the liquid metal and the transparent member.
4. The method of claim 3 wherein the at least one retaining feature is a protrusion or a void.
5. The method of claim 1 wherein a thermal expansion rate of the liquid metal is approximately equal to a thermal expansion rate of the transparent member.
6. The method of claim 1 wherein hardening the liquid metal in the mold forms a bezel that holds the transparent member.
7. A method for forming an integral assembly, the method comprising:
positioning a transparent member in a mold;
using a metal injection molding (MIM) process to provide metal around the transparent member; and
shrinking the metal at least partially around the transparent member, wherein shrinking the metal binds the metal to the transparent member to create the integral assembly.
8. The method of claim 7 wherein the transparent member is glass and the liquid metal is LiquidMetal.
9. The method of claim 7 wherein the transparent member includes at least one attachment feature, the attachment feature being positioned approximately at an edge of the transparent member.
10. The method of claim 9 wherein the at least one attachment feature includes at least one channel.
11. The method of claim 9 wherein the at least one attachment feature includes a chamfer.
12. The method of claim 7 wherein the MIM process includes centering the transparent member relative to the metal.
13. The method of claim 7 wherein shrinking the metal includes shrinking the metal by between approximately twenty percent and approximately thirty percent.
14. A method comprising:
applying at least one layer of a compliant material to an edge of a transparent member; and
binding the compliant material to an edge of a metal member arrangement, wherein binding the compliant material to the edge of the metal member arrangement creates an overall assembly.
15. The method of claim 14 further including:
applying at least one layer of the compliant material to the metal member arrangement, wherein the edge of the metal member arrangement is an edge of the at least one layer of the compliant material.
16. The method of claim 14 wherein the metal member arrangement is a bezel and the transparent member is a glass window.
17. The method of claim 14 wherein the compliant material is a gasket.
18. The method of claim 17 wherein the transparent member includes a first channel and the metal member arrangement includes a second channel, the gasket being positioned at least partially in the first channel and at least partially in the second channel.
19. The method of claim 19 wherein the gasket is arranged to provide a biasing force between the metal member arrangement and the transparent member.
20. The method of claim 14 wherein the compliant material is one selected from a group including a silicon, a rubber, a thermoplastic elastomer, and poron.
21. An apparatus comprising:
a transparent member, the transparent member including a first channel;
a metal member, the metal member including a second channel; and
a compliant material, the compliant material being arranged in the first channel and the second channel, wherein the compliant material couples the transparent member to the metal member.
22. The apparatus of claim 21 wherein the transparent member is glass and the compliant member is formed from one selected from a group including a silicon, a rubber, a thermoplastic elastomer, and poron.
23. An electronic device comprising:
an assembly, the assembly including a metal member and a transparent member with substantially no voids disposed therebetween, the metal member and the transparent member cooperating to define an exterior portion of the electronic device; and
at least one electronic element, the at least one electronic element being arranged to be at least partially covered by the assembly.
24. The electronic device of claim 23 wherein the transparent member is glass.
25. The electronic device of claim 24 wherein the metal member is a bezel.
25. The electronic device of claim 23 wherein the electronic device is a cellular phone device.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound having formula (I):
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
R1 and R2 are selected from (i), (ii), (iii), (iv) and (v) as follows:
(i) R1 and R2 together form \u2550O, \u2550S, \u2550NR9 or \u2550CR10R11;
(ii) R1 and R2 are both \u2014OR8, or R1 and R2, together with the carbon atom to which they are attached, form dioxacycloalkyl;
(iii) R1 is hydrogen or halo; and R2 is halo; and
(iv) R1 is alkyl, alkenyl, alkynyl, cycloalkyl or aryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and aryl is optionally substituted with one or more substitutents selected from halo, cyano, alkyl, \u2014RxORw, \u2014RxS(O)qRv, \u2014RxNRyRz and \u2014C(O)ORw; and R2 is hydrogen, halo or \u2014OR8; and
(v) R1 is halo, deutero, \u2014OR12, \u2014NR13R14, or \u2014S(O)qR15; and R2 is hydrogen, deutero, alkyl, alkenyl, alkynyl, cycloalkyl or aryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and aryl, is optionally substituted with one or more substitutents selected from halo, cyano, alkyl, \u2014RxORw, \u2014RxS(O)qRv and \u2014RxNRyRz;
R3 is hydrogen, halo, alkyl, cyano, haloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy or alkoxy;
R4 and R5 are each independently hydrogen or alkyl;
each R6 is independently selected from halo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, \u2014RxOR18, \u2014RxNR19R20, and \u2014RxS(O)qRv;
each R7 is independently halo, alkyl, haloalkyl or \u2014RxORw;
R8 is alkyl, alkenyl or alkynyl;
R9 is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy or amino;
R10 is hydrogen or alkyl;
R11 is hydrogen, alkyl, haloalkyl or \u2014C(O)OR8;
R12 is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, \u2014C(O)Rv, \u2014C(O)ORw and \u2014C(O)NRyRz, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio;
R13 and R14 are selected as follows:
(i) R13 is hydrogen or alkyl; and R14 is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkoxy, \u2014C(O)Rv, \u2014C(O)ORw, \u2014C(O)NRyRz and \u2014S(O)qRv, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio; or
(ii) R13 and R14, together with the nitrogen atom to which they are attached, form heterocyclyl or heteroaryl wherein the heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halo, alkyl, hydroxy, alkoxy, amino and alkylthio and wherein the heterocyclyl is also optionally substituted with oxo;
R15 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, \u2014C(O)NRyRz or \u2014NRyRz, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio;
R18 is hydrogen, alkyl, haloalkyl, hydroxyC2-6alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl; wherein R18 is optionally substituted with 1 to 3 groups Q1, each Q1 independently selected from alkyl, hydroxyl, halo, haloalkyl, alkoxy, aryloxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, hydroxycarbonyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, haloaryl and amino;
R19 and R20 are selected as follows:
(i) R19 and R20 are each independently hydrogen or alkyl; or
(ii) R19 and R20, together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl which is optionally substituted with 1 to 2 groups each independently selected from halo, alkyl, haloalkyl, hydroxyl and alkoxy;
each Rx is independently alkylene or a direct bond;
Rv is hydrogen, alkyl, alkenyl or alkynyl;
Rw is independently hydrogen, alkyl, alkenyl, alkynyl or haloalkyl;
Ry and Rz are selected as follows:
(i) Ry and Rz are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or haloalkyl;
(ii) Ry and Rz, together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl which is optionally substituted with 1 to 2 groups each independently selected from halo, alkyl, haloalkyl, hydroxyl and alkoxy;
n is 0-4;
p is 0-5; and
each q is independently 0, 1 or 2.
2. The compound of claim 1 having formula (II)
or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein
R1 and R2 are selected from (i), (ii), (iii), (iv) and (v) as follows:
(i) R1 and R2 together form \u2550O, \u2550S, \u2550NR9 or \u2550CR10R11;
(ii) R1 and R2, are both \u2014OR8, or R1 and R2, together with the carbon atom to which they are attached, form dioxacycloalkyl;
(iii) R1 is hydrogen or halo, and R2 is halo;
(iv) R1 is alkyl, alkenyl, alkynyl, cycloalkyl or aryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and aryl is optionally substituted with one or more substitutents selected from halo, alkyl, \u2014RxORw, \u2014RxS(O)qRv and \u2014RxNRyRz, and R2 is hydrogen, halo or \u2014OR8; and
(v) R1 is halo, \u2014OR12, \u2014NR13R14, \u2014S(O)qR15 or \u2014R17C(O)OR12, and R2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl and aryl is optionally substituted with one or more substitutents selected from halo, alkyl, \u2014RxORw, \u2014RxS(O)qRv and \u2014RxNRyRz;
R3 is hydrogen, alkyl or, cycloalkyl;
R4 and R5 are each independently hydrogen or alkyl;
R6a, R6b, R6c, and R6d are each independently selected from halo, alkyl, haloalkyl and \u2014RxOR18;
R7 is halo, alkyl, haloalkyl or \u2014RxORw;
R8 is alkyl, alkenyl or alkynyl;
R9 is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy or amino;
R10 is hydrogen or alkyl;
R11 is hydrogen, alkyl, haloalkyl or \u2014C(O)OR8;
each R12 is independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, thioalkyl, heterocyclylalkyl or \u2014C(O)NRyRz;
R13 and R14 are selected as follows:
(i) R13 is hydrogen or alkyl, and R14 is selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, thioalkyl, heterocycylalkyl, \u2014C(O)ORv, \u2014C(O)ORw, \u2014C(O)NRyRz and \u2014S(O)qRv; or
(ii) R13 and R14, together with the nitrogen atom to which they are attached, form heterocyclyl optionally substituted with one more more substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio;
R15 is selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, thioalkyl, heterocycylalkyl, \u2014C(O)NRyRz or \u2014NRyRz;
R18 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl; wherein R18 is optionally substituted with 1 to 3 groups Q1, where each Q1 independently selected from alkyl, hydroxyl, halo, haloalkyl, alkoxy, aryloxy, alkoxyalkyl, alkoxycarbonyl, hydroxycarbonyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, haloaryl and amino;
Rv is alkyl, alkenyl or alkynyl;
each Rx is independently alkylene or a direct bond;
Rw is independently hydrogen or alkyl;
Ry and Rz are selected as follows:
(i) Ry and Rz are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or haloalkyl; or
(ii) Ry and Rz, together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl which is optionally substituted with 1 to 2 groups each independently selected from halo, alkyl, haloalkyl, hydroxyl and alkoxy; and
each q is independently 0, 1 or 2.
3. The compound of claim 1, wherein R1 and R2 together form \u2550O
4. The compound of claim 1, wherein R1 is hydrogen or fluoro, and R2 is fluoro.
5. The compound of claim 1, wherein R1 is hydroxyl, methoxy, amino or methoxycarbonylamino, and R2 is hydrogen, phenyl or fluorophenyl.
6. The compound of claim 1, wherein R3 is hydrogen, alkyl or alkoxy.
7. The compound of claim 1, wherein each R6 is independently selected from hydrogen, halo, alkyl, hydroxyl and alkoxy.
8. The compound of claim 1, wherein R7 is halo.
9. The compound of claim 1, wherein n is 0 or 1.
10. The compound of claim 1, wherein p is 1 or 2.
11. The compound of claim 1 having formula (III) or (IIIa)
or a pharmaceutically acceptable salt thereof, wherein:
R1 and R2 are selected from (i) and (ii) as follows:
(i) R1 and R2 are both alkoxy or R1 and R2, together form \u2550O; and
(ii) R1 is \u2014OR12 or \u2014NR13 R14, and R2 is hydrogen, alkyl, aryl or haloaryl;
R12 is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, \u2014C(O)Rv, \u2014C(O)ORw and \u2014C(O)NRyRz, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl are each optionally substituted with one or more substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio;
R13 and R14 are selected as follows:
(i) R13 is hydrogen or alkyl and R14 is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkoxy, \u2014C(O)Rv, \u2014C(O)ORw, \u2014C(O)NRyRz and \u2014S(O)qRv wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl are each optionally substituted with one or more substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio; or
(ii) R13 and R14, together with the nitrogen atom to which they are attached, form heterocyclyl or heteroaryl wherein the heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halo, alkyl, hydroxy, alkoxy, amino and alkylthio and wherein the heterocyclyl is also optionally substituted with oxo;
R3 is hydrogen or alkyl;
R6 is selected from halo, alkyl, haloalkyl and \u2014RxOR18; where R18 is hydrogen, alkyl, haloalkyl, hydroxyalkyl or heterocyclyl; wherein R18 is optionally substituted with group Q1, where Q1 is selected from hydroxyl, alkoxy, alkoxycarbonyl, hydroxycarbonyl, heterocyclyl and amino;
R7 is halo, alkyl, haloalkyl, hydroxyl or alkoxy;
Rv is hydrogen, alkyl, alkenyl or alkynyl;
Rw is independently hydrogen, alkyl, alkenyl, alkynyl or haloalkyl;
Ry and Rz are selected as follows:
(i) Ry and Rz are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or haloalkyl; or
(ii) Ry and Rz, together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl which is optionally substituted with 1 to 2 groups each independently selected from halo, alkyl, haloalkyl, hydroxyl and alkoxy;
and q is 0, 1 or 2.
12. The compound of claim 1 having formula (IV) or (IVa)
or a pharmaceutically acceptable salt thereof.
13. The compound of claim 1 having formula (VI)
or a pharmaceutically acceptable salt thereof.
14. The compound of claim 1 having formula (VII)
or a pharmaceutically acceptable salt thereof.
15. The compound of claim 1 having formula (VIII)
or a pharmaceutically acceptable salt thereof.
16. The compound of claim 1 having formula (IX)
or a pharmaceutically acceptable salt thereof.
17. The compound of claim 1 having formula (X)
or a pharmaceutically acceptable salt thereof.
18. The compound of claim 1 selected from:
(4-chloroquinazolin-2-yl)(3-fluorophenyl)methanone;
(4-(1H-pyrazol-3-ylamino)quinazolin-2-yl)(3-fluorophenyl)methanone;
(4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanone;
(4-(1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanone;
(4-(1H-pyrazol-3-ylamino)quinazolin-2-yl)(2-methoxyphenyl)methanone;
(4-(1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanol;
2-(fluoro(4-fluorophenyl)methyl)-N-(1H-pyrazol-3-yl)quinazolin-4-amine;
2-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine;
2-(difluoro(4-fluorophenyl)methyl)-N-(1H-pyrazol-3-yl)quinazolin-4-amine;
N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(difluoro(4-fluorophenyl)methyl)quinazolin-4-amine;
3-(2-(4-fluorobenzoyl)quinazolin-4-ylamino)-1H-pyrazole-5-carbonitrile;
(4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanol;
2-((4-fluorophenyl)(methoxy)methyl)-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine;
2-(amino(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine;
3-(2-((4-fluorophenyl)(hydroxy)methyl)quinazolin-4-ylamino)-1H-pyrazole-5-carbonitrile;
(5-fluoro-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanol;
(4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)-7-(trifluoromethyl)quinazolin-2-yl)methanone;
(4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)-7-(trifluoromethyl)quinazolin-2-yl);
(7-fluoro-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanone;
2-(difluoro(4-fluorophenyl)methyl)-7-fluoro-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine;
2-(difluoro(4-fluorophenyl)methyl)-7-fluoro-N-(1H-pyrazol-3-yl)quinazolin-4-amine;
(4-(1H-pyrazol-3-ylamino)-7-iodoquinazolin-2-yl)(4-fluorophenyl)methanone;
(4-(1H-pyrazol-3-ylamino)-7-iodoquinazolin-2-yl)(4-fluorophenyl)methanol;
(4-fluorophenyl)(7-methyl-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanone;
(4-fluorophenyl)(7-methyl-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanol;
2-(difluoro(4-fluorophenyl)methyl)-7-methyl-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine;
2-(difluoro(4-fluorophenyl)methyl)-7-methyl-N-(1H-pyrazol-3-yl)quinazolin-4-amine;
(4-(1H-pyrazol-3-ylamino)-7-methoxyquinazolin-2-yl)(4-fluorophenyl)methanone;
(4-(1H-pyrazol-3-ylamino)-7-methoxyquinazolin-2-yl)(4-fluorophenyl)methanol;
(4-fluorophenyl)(7-methoxy-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanone;
(4-fluorophenyl)(7-methoxy-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanol;
2-(difluoro(4-fluorophenyl)methyl)-7-methoxy-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine;
2-(difluoro(4-fluorophenyl)methyl)-7-methoxy-N-(1H-pyrazol-3-yl)quinazolin-4-amine;
2-(difluoro(4-fluorophenyl)methyl)-8-fluoro-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine;
(4-(1H-pyrazol-3-ylamino)-8-methoxyquinazolin-2-yl)(4-fluorophenyl)methanone;
2-((4-fluorophenyl)(hydroxy)methyl)-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-7-ol;
(4-fluorophenyl)(7-hydroxy-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanone;
(4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)-7-(2-morpholinoethoxy)quinazolin-2-yl)methanol;
2-(2-((4-fluorophenyl)(hydroxy)methyl)-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-7-yloxy)ethanol;
3-(2-((4-fluorophenyl)(hydroxy)methyl)-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-7-yloxy)propan-1-ol;
(4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)-7-(piperidin-4-yloxy)quinazolin-2-yl)methanol;
(4-fluorophenyl)(7-(2-methoxyethoxy)-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanol;
tert-butyl 2-(2-((4-fluorophenyl)(hydroxy)methyl)-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-7-yloxy)acetate;
2-(2-((4-fluorophenyl)(hydroxy)methyl)-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-7-yloxy)acetic acid;
{(4-fluoro-phenyl)-4-(5-methyl-1H-pyrazol-3-ylamino)-quinazolin-2-yl-methyl}-carbamic acid methyl ester;
bis-(4-fluoro-phenyl)-4-(5-methyl-1H-pyrazol-3-ylamino)-quinazolin-2-yl-methanol;
methyl(4-fluorophenyl)(4-(5-methyl-4H-pyrazol-3-ylamino)quinazolin-2-yl)methylcarbamate;
(4-fluorophenyl)(8-methyl-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanol;
(7-fluoro-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanol;
(4-(1H-pyrazol-3-ylamino)quinazolin-2-yl)bis(4-fluorophenyl)methanol;
(2-(difluoro(4-fluorophenyl)methyl)-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-7-yl)methanol;
2-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-7-(methylsulfonylmethyl)quinazolin-4-amine;
2-(Difluoro(4-fluorophenyl)methyl)-7-(ethoxymethyl)-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine;
(7-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanol;
(6-fluoro-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanone-(6-fluoro-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanol;
(4-(1H-pyrazol-3-ylamino)-6-fluoroquinazolin-2-yl)(4-fluorophenyl)methanol;
(7-bromo-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanone;
(7-bromo-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanol;
(4-(1H-pyrazol-3-ylamino)-7-bromoquinazolin-2-yl)(4-fluorophenyl)methanol;
2-(2-(4-fluorophenyl)-1,3-dioxolan-2-yl)-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine;
(8-fluoro-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanone;
(8-fluoro-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanol;
(2-methoxyphenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanone;
(2-methoxyphenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanol;
(3-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanol;
N-((4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methyl)formamide;
(3,4-difluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanol;
(3-chloro-4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanol;
3-(4-fluorophenyl)-3-(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)propanenitrile;
2-((cyclopropylamino)(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine;
2-(1-(4-fluorophenyl)-2-(methylsulfonyl)ethyl)-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine;
2-(3-amino-1-(4-fluorophenyl)propyl)-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine;
(4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanol-1-d;
(4-fluorophenyl)(4-(5-methoxy-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanone;
(4-(5-ethyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanol;
(4-Fluorophenyl)(4-(5-methoxy-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanol;
(4-fluoro-3-methoxyphenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanone;
(4-fluoro-3-hydroxyphenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanone; and
(2-fluoro-5-(hydroxy(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methyl)phenol acetate.
19. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.
20. A method for treatment of a JAK modulated disease comprising administering a therapeutically effective amount of a compound of claim 1.
21. A method for treatment of a JAK2 modulated disease comprising administering a therapeutically effective amount of a compound of claim 1.
22. The method of claim 21, wherein JAK2 is wild type or mutant JAK2.
23. The method of claim 20, wherein the disease is cancer, myeloproliferative disorder, inflammation or autoimmune disease.
24. The method of claim 20, further comprising administering a second pharmaceutical agent selected from anti-proliferative agent, anti-inflammatory agent, immunomodulatory agent and immunosuppressive agent.
25. The compound of claim 1 for use in treatment of a JAK modulated disease.
26. Use of the compound of claim 1 for preparation of a medicament for treating a JAK modulated disease.